William P Tew1, Christina Lacchetti2, Annie Ellis3,4, Kathleen Maxian5, Susana Banerjee6, Michael Bookman7, Monica Brown Jones8, Jung-Min Lee9, Stéphanie Lheureux10, Joyce F Liu11, Kathleen N Moore12, Carolyn Muller13, Patricia Rodriguez14, Christine Walsh15, Shannon N Westin16, Elise C Kohn9. 1. Memorial Sloan Kettering Cancer Center, New York, NY. 2. American Society of Clinical Oncology, Alexandria, VA. 3. SHARE Cancer Support, New York, NY. 4. Ovarian Cancer Research Alliance, New York, NY. 5. Ovarian Cancer Project, Williamsville, NY. 6. The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom. 7. Kaiser Permanente, San Francisco, CA. 8. DeCesaris Cancer Institute, Anne Arundel Medical Center, Annapolis, MD. 9. National Cancer Institute, Bethesda, MD. 10. University Health Network, Toronto, Ontario, Canada. 11. Dana-Farber Cancer Institute, Boston, MA. 12. Stephenson Cancer Center, Oklahoma City, OK. 13. University of New Mexico, Albuquerque, NM. 14. Virginia Cancer Specialists, Arlington, VA. 15. Cedars-Sinai, West Hollywood, CA. 16. University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
PURPOSE: To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). METHODS: Randomized, controlled, and open-labeled trials published from 2011 through 2020 were identified in a literature search. Guideline recommendations were based on the review of the evidence, US Food and Drug Administration approvals, and consensus when evidence was lacking. RESULTS: The systematic review identified 17 eligible trials. RECOMMENDATIONS: The guideline pertains to patients who are PARPi naïve. All patients with newly diagnosed, stage III-IV EOC whose disease is in complete or partial response to first-line, platinum-based chemotherapy with high-grade serous or endometrioid EOC should be offered PARPi maintenance therapy with niraparib. For patients with germline or somatic pathogenic or likely pathogenic variants in BRCA1 (g/sBRCA1) or BRCA2 (g/sBRCA2) genes should be treated with olaparib. The addition of olaparib to bevacizumab may be offered to patients with stage III-IV EOC with g/sBRCA1/2 and/or genomic instability and a partial or complete response to chemotherapy plus bevacizumab combination. Maintenance therapy (second line or more) with single-agent PARPi may be offered for patients with EOC who have not received a PARPi and have responded to platinum-based therapy regardless of BRCA mutation status. Treatment with a PARPi should be offered to patients with recurrent EOC that has not recurred within 6 months of platinum-based therapy, who have not received a PARPi and have a g/sBRCA1/2, or whose tumor demonstrates genomic instability. PARPis are not recommended for use in combination with chemotherapy, other targeted agents, or immune-oncology agents in the recurrent setting outside the context of a clinical trial. Recommendations for managing specific adverse events are presented. Data to support reuse of PARPis in any setting are needed.Additional information is available at www.asco.org/gynecologic-cancer-guidelines.
PURPOSE: To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). METHODS: Randomized, controlled, and open-labeled trials published from 2011 through 2020 were identified in a literature search. Guideline recommendations were based on the review of the evidence, US Food and Drug Administration approvals, and consensus when evidence was lacking. RESULTS: The systematic review identified 17 eligible trials. RECOMMENDATIONS: The guideline pertains to patients who are PARPi naïve. All patients with newly diagnosed, stage III-IV EOC whose disease is in complete or partial response to first-line, platinum-based chemotherapy with high-grade serous or endometrioid EOC should be offered PARPi maintenance therapy with niraparib. For patients with germline or somatic pathogenic or likely pathogenic variants in BRCA1 (g/sBRCA1) or BRCA2 (g/sBRCA2) genes should be treated with olaparib. The addition of olaparib to bevacizumab may be offered to patients with stage III-IV EOC with g/sBRCA1/2 and/or genomic instability and a partial or complete response to chemotherapy plus bevacizumab combination. Maintenance therapy (second line or more) with single-agent PARPi may be offered for patients with EOC who have not received a PARPi and have responded to platinum-based therapy regardless of BRCA mutation status. Treatment with a PARPi should be offered to patients with recurrent EOC that has not recurred within 6 months of platinum-based therapy, who have not received a PARPi and have a g/sBRCA1/2, or whose tumor demonstrates genomic instability. PARPis are not recommended for use in combination with chemotherapy, other targeted agents, or immune-oncology agents in the recurrent setting outside the context of a clinical trial. Recommendations for managing specific adverse events are presented. Data to support reuse of PARPis in any setting are needed.Additional information is available at www.asco.org/gynecologic-cancer-guidelines.
Authors: Bella Kaufman; Ronnie Shapira-Frommer; Rita K Schmutzler; M William Audeh; Michael Friedlander; Judith Balmaña; Gillian Mitchell; Georgeta Fried; Salomon M Stemmer; Ayala Hubert; Ora Rosengarten; Mariana Steiner; Niklas Loman; Karin Bowen; Anitra Fielding; Susan M Domchek Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544
Authors: Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Courtney Tyne; Douglas W Blayney; Diane Blum; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Richard L Schilsky Journal: J Clin Oncol Date: 2015-06-22 Impact factor: 44.544
Authors: Antonio González-Martín; Bhavana Pothuri; Ignace Vergote; René DePont Christensen; Whitney Graybill; Mansoor R Mirza; Colleen McCormick; Domenica Lorusso; Paul Hoskins; Gilles Freyer; Klaus Baumann; Kris Jardon; Andrés Redondo; Richard G Moore; Christof Vulsteke; Roisin E O'Cearbhaill; Bente Lund; Floor Backes; Pilar Barretina-Ginesta; Ashley F Haggerty; Maria J Rubio-Pérez; Mark S Shahin; Giorgia Mangili; William H Bradley; Ilan Bruchim; Kaiming Sun; Izabela A Malinowska; Yong Li; Divya Gupta; Bradley J Monk Journal: N Engl J Med Date: 2019-09-28 Impact factor: 91.245
Authors: Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Douglas W Blayney; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Julie M Vose; Richard L Schilsky Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Karen A Gelmon; Marc Tischkowitz; Helen Mackay; Kenneth Swenerton; André Robidoux; Katia Tonkin; Hal Hirte; David Huntsman; Mark Clemons; Blake Gilks; Rinat Yerushalmi; Euan Macpherson; James Carmichael; Amit Oza Journal: Lancet Oncol Date: 2011-08-19 Impact factor: 41.316
Authors: Elizabeth M Swisher; Kevin K Lin; Amit M Oza; Clare L Scott; Heidi Giordano; James Sun; Gottfried E Konecny; Robert L Coleman; Anna V Tinker; David M O'Malley; Rebecca S Kristeleit; Ling Ma; Katherine M Bell-McGuinn; James D Brenton; Janiel M Cragun; Ana Oaknin; Isabelle Ray-Coquard; Maria I Harrell; Elaina Mann; Scott H Kaufmann; Anne Floquet; Alexandra Leary; Thomas C Harding; Sandra Goble; Lara Maloney; Jeff Isaacson; Andrew R Allen; Lindsey Rolfe; Roman Yelensky; Mitch Raponi; Iain A McNeish Journal: Lancet Oncol Date: 2016-11-29 Impact factor: 41.316
Authors: Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: Shiyu Zhang; Robert Royer; Song Li; John R McLaughlin; Barry Rosen; Harvey A Risch; Isabel Fan; Linda Bradley; Patricia A Shaw; Steven A Narod Journal: Gynecol Oncol Date: 2011-02-15 Impact factor: 5.482
Authors: Amit M Oza; David Cibula; Ana Oaknin Benzaquen; Christopher Poole; Ron H J Mathijssen; Gabe S Sonke; Nicoletta Colombo; Jiří Špaček; Peter Vuylsteke; Holger Hirte; Sven Mahner; Marie Plante; Barbara Schmalfeldt; Helen Mackay; Jacqui Rowbottom; Elizabeth S Lowe; Brian Dougherty; J Carl Barrett; Michael Friedlander Journal: Lancet Oncol Date: 2014-12-04 Impact factor: 41.316
Authors: Alexandra Lainé; Travis T Sims; Olivia Le Saux; Isabelle Ray-Coquard; Robert L Coleman Journal: Curr Oncol Rep Date: 2021-11-09 Impact factor: 5.075
Authors: F Guffanti; M F Alvisi; A Anastasia; F Ricci; M Chiappa; A Llop-Guevara; V Serra; R Fruscio; A Degasperi; S Nik-Zainal; M R Bani; M Lupia; R Giavazzi; E Rulli; G Damia Journal: Br J Cancer Date: 2021-11-03 Impact factor: 7.640